The European Medicines Agency (EMA) and the Heads of Medicines Agency (HMA) have adopted their joint network strategy to 2025.
The strategy focuses on six priority regulatory areas:
- Availability and accessibility of medicines;
- Data analytics, digital tools and digital transformation;
- Antimicrobial resistance and other emerging health threats;
- Supply chain challenges;
- The sustainability of the network and operational excellence.
For each of these priority areas, strategic goals are highlighted with recommendations to help achieve those goals.
The document provides a high-level overview of the EU network’s strategy over the next five years, with more specific details to follow in working plans being developed by EMA and HMA. It also reflects on lessons learned from the COVID-19 pandemic such as an acknowledgement of the potential to use real-world data to evaluate health policy.
This strategy is aligned with the European Commission’s (EC) recently adopted pharmaceutical strategy.
For more information, click here.